Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Davis

Writer

London, U.K
A journalist and editor for more than 30 years, John has a broad interest in pharmaceuticals-related health care policy and breakthroughs in scientific and medical research.  He has degrees in biology and biochemical pharmacology.
Advertisement
Set Alert for Articles By John Davis

Latest From John Davis

Sanofi's Generics Business To Be Sold To Private Equity Firm, Advent

Sanofi will have €1.9bn to add to its war-chest when it concludes the sale of its European generics business.

Generic Drugs Financing

Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive answer about its effects on overall survival.

 

Clinical Trials Cancer

Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 


Pipeline Watch Approvals

Sanofi Underpins Vaccine Strategy With New Manufacturing Facilities

Sanofi's major investments in vaccine manufacturing are continuing with the expansion of its Toronto, Canada facility, to be completed in 2021.

Manufacturing Vaccines

Pfizer's Axitinib Disappoints As RCC Adjuvant Therapy

An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.

Cancer Clinical Trials

Executive Interview: Vectura's Ward-Lilley On Re-Focusing On The Respiratory Sector

Respiratory delivery specialist Vectura is to concentrate on developing enhanced inhaled products, as well as substitutable inhaled generics for the US market, and is pulling back from NME work. CEO James Ward-Lilley explains why.

 

Respiratory Generic Drugs
See All
Advertisement
UsernamePublicRestriction

Register